Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Lancet Oncology

• Publication date

  2014-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(14)70420-6PMID 25240821
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

  2014cited by this paper
• Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

  2013cited by this paper
• Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

  2013cited by this paper
• Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

  2013cited by this paper
• Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

  2013cited by this paper
• GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer

  2013cited by this paper
• Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

  2012cited by this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.

  2012cited by this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

  2011cited by this paper
• Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

  2011cited by this paper
• Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel.

  2010cited by this paper
• Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

  2010cited by this paper
• A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

  2008cited by this paper
• A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).

  2007cited by this paper
• Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

  2006cited by this paper
• Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.

  2006cited by this paper
• Molekular zielgerichtete Therapie

  2006cited by this paper
• Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

  2006cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model.

  2002cited by this paper
• [Advanced gastric cancer].

  2001cited by this paper
• Phase II study of paclitaxel in pretreated advanced gastric cancer

  1998cited by this paper
• Interpreting the significance of changes in health-related quality-of-life scores.

  1998cited by this paper
• Modeling valuations for EuroQol health states.

  1997cited by this paper
• The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

  1993cited by this paper
• EuroQol--a new facility for the measurement of health-related quality of life.

  1990cited by this paper
• EuroQol : a new facility for the measurement of health-related quality of life

  1990cited by this paper
• Asymmetric group sequential boundaries for monitoring clinical trials

  1982cited by this paper

• Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial.

  2026cites this paper
• Cost-effectiveness of sugemalimab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced oesophageal squamous cell carcinoma in China

  2026cites this paper
• Apatinib in combination with docetaxel and S-1 chemotherapy as first-line treatment for metastatic gastric cancer.

  2026cites this paper
• Japanese gastric cancer treatment guidelines 2025 (7th edition)

  2026cites this paper
• [Oligometastasis in the gastrointestinal tract].

  2026cites this paper
• Cost-effectiveness of perioperative durvalumab plus FLOT for resectable gastric and gastroesophageal junction adenocarcinoma in the United States.

  2026cites this paper
• Relative Clinical Efficacy and Safety of Second- or Later-Line Treatments for Advanced and Metastatic Gastric Cancer: A Rapid Review and Network Meta-Analysis

  2026cites this paper
• TROP2-Targeted Therapeutics in Development to Treat Gastrointestinal Tumors.

  2026cites this paper
• Targeting Esophageal Cancer: Promising Drugs for the Clinical Landscape and Key Knowledge Gaps

  2026cites this paper
• Prognostic impact of TROP2 in adenocarcinoma of the esophageal junction and stomach.

  2026influential citation
• A dimer peptide ligand of vascular endothelial growth factor slows the progression of human gastric tumors in mouse xenografts

  2026cites this paper
• Adenocarcinoma of the esophagus and gastroesophageal junction: The evolving treatment landscape for locally advanced and metastatic disease in the era of immune checkpoint inhibitors and biomarker‐driven therapeutics

  2026cites this paper
• Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers

  2026cites this paper
• Effect of ramucirumab and bevacizumab in an experimental diabetic retinopathy rat model: A pilot study.

  2026cites this paper
• Outcomes of Ramucirumab Monotherapy for Advanced Gastric Cancer in a Multi-institutional Cohort Study in Japan

  2026cites this paper
• Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan

  2026cites this paper
• Efficacy and safety of cadonilimab combined with chemotherapy for gastric or gastroesophageal junction adenocarcinoma: a single-arm meta-analysis.

  2026cites this paper
• BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer

  2026cites this paper
• Poliovirus Receptor as a Potential Target in Gastric Signet-Ring Cell Carcinoma for Antibody-Drug Conjugate Development

  2026cites this paper
• Impact of vascular endothelial growth factor inhibitor-induced hypertension on continued cancer treatment: a systematic review and meta-analysis.

  2026cites this paper
• Capillary Hemangioma of the Breast Parenchyma Mimicking New Primary Cancer or Metastasis During Ramucirumab Therapy for Advanced Gastric Cancer

  2026cites this paper
• Integrated network toxicology, machine learning algorithms and TMT proteomics reveal the mechanism of 18β glycyrrhetinic acid against gastric cancer

  2026cites this paper
• What determines value? Exploring value characteristics of novel therapies for digestive system cancers.

  2026cites this paper
• Ramucirumab‐containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum‐based chemotherapy: A multicenter observational retrospective study (WJOG13420G)

  2025cites this paper
• [Another sight at Gastric Cancer Molecular Classification: novel subtypes based on expression of CDX-2, E-cadherin, Epstein-Barr virus RNAs, MMR proteins].

  2025cites this paper
• Carcinoma of Esophagus

  2025cites this paper
• A cost-effectiveness analysis of the effect of hospital variation in the probability of providing treatment with curative intent in potentially curable esophageal and gastric cancer patients

  2025cites this paper
• Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases

  2025cites this paper
• Pharmacometric and Digital Twin modeling for adaptive scheduling of combination therapy in advanced gastric cancer

  2025cites this paper
• DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

  2025influential citation
• Antitumor effects of plasma-activated sodium acetate solution on gastric cancer cells

  2025cites this paper
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

  2025cites this paper
• The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study

  2025cites this paper
• Novel immunotherapy for gastric cancer: targeting the CD47–SIRPα axis

  2025influential citation
• Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

  2025cites this paper
• Two decades of progress in gastric cancer peritoneal metastasis: a bibliometric perspective on molecular mechanisms and therapeutic innovations

  2025cites this paper
• Sugemalimab plus chemotherapy vs. chemotherapy for treatment of Chinese patients with esophageal squamous cell carcinoma: a cost effectiveness analysis to inform decision making

  2025cites this paper
• CC48 a new CB2R agonist/FAAH inhibitor dual drug blocks gastric cancer progression and overcomes paclitaxel resistance

  2025cites this paper
• Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer.

  2025cites this paper
• Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer

  2025cites this paper
• Neue Ansätze in der Immuntherapie gastrointestinaler Tumoren

  2025cites this paper
• First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials

  2025cites this paper
• Pyrotinib monotherapy for advanced HER2-positive esophageal adenocarcinoma with trastuzumab resistance and chemotherapy intolerance: a case report and literature review

  2025influential citation
• Unveiling the Novel Anti - Tumor Potential of Digitonin, a Steroidal Saponin, in Gastric Cancer: A Network Pharmacology and Experimental Validation Study

  2025cites this paper
• Unravelling Paclitaxel Resistance in Gastric Cancer: The Role of Small Extracellular Vesicles in Epithelial Mesenchymal Transition and Extracellular Matrix Remodelling

  2025cites this paper
• Maintenance Capecitabine Plus Ramucirumab After First-Line Chemotherapy in Patients With Advanced Esophagogastric Adenocarcinoma: Results From the Randomized PLATFORM Study

  2025cites this paper
• Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58–UCGI35–REGIRI Unicancer randomised phase II study

  2025cites this paper
• Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer

  2025cites this paper
• Prognostic impact of conversion surgery in patients with stage IV gastric cancer: A multicenter population-based cohort study.

  2025cites this paper
• HRD1 regulates tumor-associated macrophage polarization through USP7 and promotes lung cancer development.

  2025cites this paper
• Advanced therapies for stomach cancer

  2025cites this paper
• Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.

  2025cites this paper
• Synergistic immunotherapy in pancreatic cancer: a case study and in-depth review

  2025cites this paper
• Targeted therapies in neoadjuvant treatment for gastroesophageal cancer

  2025cites this paper
• WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)

  2025cites this paper
• Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond

  2025cites this paper
• Mendelian randomization studies of gastric cancer reveal potential risk factors, promising biomarkers and therapeutic targets

  2025cites this paper
• Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial

  2025cites this paper
• Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer

  2025cites this paper
• Impact of Pre-treatment Proteinuria Progression on the Risk of Increased Proteinuria During Ramucirumab Therapy

  2025cites this paper
• Association between increased proteinuria induced by Bevacizumab, Ramucirumab, and Aflibercept and the risk of renal impairment and failure: a systematic review and meta-analysis

  2025cites this paper
• ONO‐4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer

  2025cites this paper
• Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)

  2025cites this paper
• Comparison of the prognostic effect of taxane regimens combined with ramucirumab before nivolumab for advanced gastric cancer

  2025cites this paper
• Immunotherapy or Targeted Therapy Versus Best Supportive Care for Advanced Gastric Cancer: A Systematic Review and Meta-analysis of Randomized Trials

  2025cites this paper
• Exploring the Novel Role and Mechanistic Insights of Skeletal Muscle Relaxant Cyclobenzaprine Hydrochloride in Esophageal Squamous Cell Carcinoma Treatment.

  2025cites this paper
• Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project

  2025cites this paper
• Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies

  2025cites this paper
• Molecular mechanisms of metastatic peritoneal dissemination in gastric adenocarcinoma

  2025cites this paper
• Reversal of chemotherapy resistance in gastric cancer with traditional Chinese medicine as sensitizer: potential mechanism of action

  2025cites this paper
• Actualización del cáncer gástrico

  2025cites this paper
• Association between adjuvant radiotherapy in adults with gastric cancer and risk of second primary malignancy: a retrospective cohort study using the Surveillance, Epidemiology and End Results database

  2025cites this paper
• Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview

  2025cites this paper
• Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study

  2025cites this paper
• Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)

  2025cites this paper
• Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives

  2025influential citation
• Metastatic gastric cancer in fit patients—a practical algorithm of treatment sequencing from the Brazilian Group of Gastrointestinal Tumours (GTG)

  2025cites this paper
• Outcomes of patients with refractory upper GI cancers enrolled in phase I trials: a 10-year analysis from the Sarah Cannon Research Institute UK Drug Development Unit

  2025influential citation
• Evaluating the pharmacokinetics of zolbetuximab in gastric adenocarcinoma

  2025cites this paper
• Educational Review: Updates on Therapeutic Strategies for Gastric Cancer with Peritoneal Metastasis

  2025influential citation
• Global alliances in translational cancer research.

  2025cites this paper
• A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy

  2025cites this paper
• Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal Metastases.

  2025cites this paper
• Gastric cancer peritoneal metastasis: a bibliometric study from 2000 to 2024 using VOSviewer software

  2025cites this paper
• Artificial intelligence-driven integration of single-cell RNA sequencing and transcriptome analysis to decipher APOE’s role in gastric cancer prognosis and therapy

  2025cites this paper
• Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review.

  2025cites this paper
• Global trends in esophageal cancer and metabolic syndrome research: bibliometric analysis and visualization from 1995 to 2024

  2025cites this paper
• Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center study

  2025cites this paper
• Efficacy and adverse events of immune checkpoint inhibitors: evidence on non-small cell lung cancer and gastric cancer from Korea and Japan

  2025cites this paper
• The Role of Placental Growth Factor (PlGF) as a Biomarker in Patients with Resectable Gastric Cancer.

  2025cites this paper
• Survival outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in selected patients with stage IV gastric adenocarcinoma - A Canadian case series.

  2025cites this paper
• Angiogenesis causes and vasculogenic mimicry formation in the context of cancer stem cells.

  2025cites this paper
• Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma

  2025cites this paper
• Role of tumor suppressor genes P53 and PTEN in CD44-mediated gastric adenocarcinoma multidrug resistance.

  2025cites this paper
• ZIP8 modulates ferroptosis to drive esophageal carcinoma progression

  2025cites this paper
• Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• Treatment Options for Metastatic Gastric Cancer After Recurrence Following Perioperative FLOT: A Critical Review

  2025cites this paper
• “Attenuated” Pulmonary Tumor Thrombotic Microangiopathy on Anti-Vascular Endothelial Growth Factor Treatment: A Case Report

  2025cites this paper
• Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration

  2025cites this paper
• Contemporary management of advanced gastric and gastroesophageal adenocarcinomas

  2025influential citation